Research output per year
Research output per year
Search results
-
2022
Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naive Patients with Chronic Lymphocytic Leukemia without Del17p/TP53-Mutation Compared to Chlorambucil Plus Obinutuzumab
Slot, M., Niemann, C. U., Risor, B. W., Ehlers, L. H. & Rotbain, E., 15 Nov 2022, In: Blood. 140, Suppl. 1, p. 2163-2164 2 p., 902.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review